» Articles » PMID: 10898512

Fusogenic Liposomes Efficiently Deliver Exogenous Antigen Through the Cytoplasm into the MHC Class I Processing Pathway

Overview
Journal Eur J Immunol
Date 2000 Jul 18
PMID 10898512
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Exogenous soluble proteins enter the endosomal pathway by endocytosis and are presented in association with MHC class II rather than class I. In contrast, the delivery of exogenous protein antigens (Ag) into the cytosol generates MHC class I-restricted cytotoxic T lymphocytes (CTL) responses. Although several immunization approaches, such as the utilization of liposomes, have induced the in vivo priming of MHC class I-restricted CTL responses to protein Ag, it remains unclear whether this priming results from the direct delivery of protein Ag to the cytosol. Here we report that fusogenic liposomes (FL), which are prepared by fusing simple liposomes with Sendai virus particles, can deliver the encapsulated soluble protein directly into the cytosol of cells cultured concurrently and introduce it into the conventional MHC class I Ag presentation pathway. Moreover, a single immunization with ovalbumin (OVA) encapsulated in FL but not in simple liposomes results in the potent priming of OVA-specific CTL. Thus, FL function as an efficient tool for the delivery of CTL vaccines.

Citing Articles

Virosome: An engineered virus for vaccine delivery.

Ali H, Akbar M, Iqbal B, Ali F, Sharma N, Kumar N Saudi Pharm J. 2023; 31(5):752-764.

PMID: 37181145 PMC: 10172599. DOI: 10.1016/j.jsps.2023.03.016.


Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol.

Nakhaei P, Margiana R, Bokov D, Abdelbasset W, Jadidi Kouhbanani M, Varma R Front Bioeng Biotechnol. 2021; 9:705886.

PMID: 34568298 PMC: 8459376. DOI: 10.3389/fbioe.2021.705886.


Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery.

Yuba E, Fukaya Y, Yanagihara S, Kasho N, Harada A Pharmaceutics. 2020; 12(8).

PMID: 32796567 PMC: 7465930. DOI: 10.3390/pharmaceutics12080754.


Liposomal adjuvant development for leishmaniasis vaccines.

Askarizadeh A, Jaafari M, Khamesipour A, Badiee A Ther Adv Vaccines. 2017; 5(4-5):85-101.

PMID: 29201374 PMC: 5697592. DOI: 10.1177/2051013617741578.


Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Ikehara Y, Yamanaka M, Yamaguchi T J Biomed Biotechnol. 2010; 2010:242539.

PMID: 20617143 PMC: 2896661. DOI: 10.1155/2010/242539.